Must-know: Why Maverick adds new position in Ashland
Ashland has seen pressure from activist investor JANA Partners, which acquired a stake in the chemical maker in April, 2013, to boost shareholder value.
4Q14 Updates to Pershing Square Holdings
Pershing Square Holdings filed its fourth quarter 13F last month. The fund’s US long portfolio rose to $16.04 billion, from $13.4 billion in 4Q14.
Eli Lilly and Co.’s Strong Q1 Results, Updated 2018 Guidance
Eli Lilly and Co. reported revenues of ~$5.7 billion for 1Q18 today, reflecting 9% growth from 1Q17.
How Merial Contributes to Sanofi’s Growth
Merial, Sanofi’s (SNY) Animal Health segment, reported total revenues of 725 million euros (about $818.6 million), which is a 9.1% increase over 2Q15.
How Did Merial Contribute to Sanofi’s 2Q15 Growth?
Merial reported total revenues of 691 million euros, a 14.2% increase at constant exchange rates over 2Q14.
Pershing Square takes on Zoetis, adds to Canadian Pacific in 3Q14
Activist hedge fund manager William Ackman’s Pershing Square Capital Holdings filed its third quarter 13F last month. The fund’s year-to-date returns as of October 31, 2014, net of fees, was 35.0%.
Zoetis: An attractive business model
Zoetis said in a recent statement that “its unique characteristics have established the company as the world leader in animal health, growing revenue faster than the market for the last three years.”
Must-know trends that drive Zoetis’ growth
Demand for Zoetis’ products is driven by a growing population coupled with a rising middle class in emerging markets and increased relocation from rural to urban areas.
Pershing Square adds to positions in Freddie Mac and Fannie Mae
Pershing Square Management added more shares in mortgage financiers Freddie Mac (FMCC) and Fannie Mae (FNMA) during the drop in stock prices in October.
Align Technology Stock Recovers after Tanking Last Week
Align Technology stock (ALGN) took a massive hit after Q2 earnings. So what was behind the massive decline, and what’s helping the stock recover?
What Are the Major Risks Affecting Elanco Animal Health?
In its fourth-quarter earnings conference call, Elanco Animal Health (ELAN) reported a 4% YoY drop in sales driven by a 9% decline in sales volumes.
Henry Schein to Merge Animal Health with Vets First Choice
On April 23, Henry Schein (HSIC) announced its plans to spin off and merge its animal health business with Vets First Choice to form a joint venture, Vets First Corp.
Key Risks Facing PetMed Express in 2017
PetMed Express (PETS) stock has risen 77% in the last one-year period, reaching a high of $50.06 on July 26, 2017.
New Customer Acquisition Drives Revenue Growth for PetMed Express
In 2017, the PetMed Express (PETS) website attracted ~32.0 million visitors, ~8.0% of whom placed an order for a conversion ratio of ~25.0%.
Analysts’ Recommendations for PetMed Express and Peers in 2017
Of the five analysts covering PetMed Express (PETS) in October 2017, two gave it “strong buy” ratings, two gave it “hold” ratings, and one gave it a “sell” rating. Its target price was $43.75.
Behind Merck’s Animal Health Segment Performance in 2Q17
Merck’s (MRK) Animal Health segment includes drugs and vaccines for animals and has operations spread across more than 140 countries worldwide.
Inside Merck’s Segment-Wise Performance in 2Q17
Merck’s Pharmaceuticals segment contributed ~88.2% of total revenues in 2Q17, reporting $8.76 billion.
US Pharmaceuticals: Mergers and Acquisitions in 2Q17
The US pharmaceutical sector comprises different setups pertaining to the development, manufacturing, production, and marketing of drugs. Let’s look at its performance in 2Q17.
Performance of Zoetis Stock in 2Q17
Zoetis (ZTS) stock has risen ~17.3% in 2Q17, while it has risen ~15.4% year-to-date as of July 7, 2017.
What’s Really Driving Zoetis’s Margins in 2017?
Zoetis (ZTS) expects to generate savings of over $300 million in 2017 through its operational efficiency program.
Why Zoetis’s Apoquel and Cytopoint Are Expected to Report Robust Revenues
In 1Q17, Zoetis’s (ZTS) dermatology portfolio reported revenues of ~$57 million, driven by the steady adoption of Cytopoint and Apoquel.
Why Zoetis Expects to See Robust Revenue Growth in 2017
Zoetis (ZTS) has adopted a targeted R&D strategy that has resulted in multiple new product launches.
Performance of Eli Lilly & Co.’s Elanco in 1Q17
Eli Lilly & Co.’s (LLY) Animal Health company, Elanco, reported an increase of 2% in revenues to $769.4 million in 1Q17, compared to $754.6 million in 1Q16.
Eli Lilly’s 1Q17 Estimates for Elanco
Eli Lilly’s (LLY) animal health segment, Elanco, deals with products for companion animals as well as food and other products.
How Eli Lilly’s Elanco Performed in 2016
Eli Lilly’s (LLY) Animal Health segment’s company, Elanco, reported a fall of 1% in its revenue to $3.16 billion in 2016, compared to $3.18 billion in 2015.
What to Expect from Eli Lilly’s Elanco in 4Q16
Eli Lily’s US animal health revenues are expected to remain nearly constant during 4Q16.
Word on the Street about Merck’s Animal Health Segment
Merck & Co.’s (MRK) Animal Health segment operates in more than 140 countries worldwide. Global sales for the segment are expected to rise to $915 million in 3Q16.
Mylan’s Business Model: A Key Investor Rundown
In 2014, Mylan earned about 85% of its total revenues from the US generic market, which is the largest generic market in the world.
A Key Look at Abbott Laboratories’ Acquisitions and Divestments
Inorganic growth through acquisitions has led to the expansion of Abbott Laboratories across geographies and to the broadening of its product portfolio.
Changes in Merck & Co.’s Reported Business Segments in 2015
The Global Human Health, or Pharmaceuticals, segment generates the most revenue for Merck. It contributed nearly 85% of the total revenue in 2014.
Merck: Other Human Health Franchise and Animal Health Segment
The animal health segment contributed ~8% of the total revenue in 2014. This contribution rose to ~9% for 2Q15 due to a rise in revenue by 10%.
Highfields Capital Adds Zoetis to Its 4Q14 Portfolio
Zoetis (ZTS) is the animal health business that Pfizer (PFE) spun off in June 2013.